Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma

Jorge Marrero, Mary A. Maluccio, Heather McCurdy, Ghassan K. Abou-Alfa

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Dr Marrero is a consultant with and serves on the advisory boards for Onyx Pharmaceuticals and Bayer. Dr Maluccio has no relevant financial relationships with commercial interests to disclose. Ms McCurdy is on the speakers' bureau for Onyx Pharmaceuticals. Dr Abou-Alfa and/or his spouse serve as a consultant for Aduro Biotech, Astellas Pharma US, AstraZeneca, Bayer, Celgene, Celsion, Eli Lilly and Company, Exelixis, Genentech, IntegraGen, Jennerex Biotherapeutics, MedImmune, Novartis, Pharmacyclics, Roche, sanofi-aventis, Silenseed, and Vicus Therapeutics. He and/or his spouse have received research grants from Abbott Laboratories, Amgen, Bayer, Eli Lilly and Company, Exelixis, Genentech, Momenta Pharmaceuticals, Myriad Genetics, Novartis, OncoMed Pharmaceuticals, Polaris Pharmaceuticals, Roche, sanofi-aventis, and Vicus Therapeutics.

Original languageEnglish (US)
Pages (from-to)5-16
Number of pages12
JournalCancer Control
Volume21
Issue number2 SUPPL
StatePublished - Apr 2014

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this